BMJ Open (Jun 2022)
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
- Roger Owen,
- John Jones,
- David Meads,
- David A Cairns,
- Christopher Parrish,
- Gordon Cook,
- Neil Rabin,
- Matthew Jenner,
- Martin Kaiser,
- Kevin Boyd,
- Graham Jackson,
- Catherine Olivier,
- Amy Beth Coulson,
- Kara-Louise Royle,
- Charlotte Pawlyn,
- Anna Hockaday,
- Jennifer Bird,
- Stella Bowcock,
- Ruth de Tute,
- Hayley Gardner,
- Bryony Dawkins,
- Rowena Henderson,
- Phillip Best,
- Bhuvan Kishore,
- Mark Drayson
Affiliations
- Roger Owen
- 2 Department of Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- John Jones
- King`s College Hospital, London, UK
- David Meads
- Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
- David A Cairns
- 1 Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, West Yorkshire, UK
- Christopher Parrish
- Department of Haematology, St James`s University Hospital, Leeds, UK
- Gordon Cook
- Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
- Neil Rabin
- 5 Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
- Matthew Jenner
- Department of Haematology, Southampton General Hospital, Southampton, UK
- Martin Kaiser
- Centre for Myeloma Research, Institute of Cancer Research, London, UK
- Kevin Boyd
- 3Fédération Internationale de Natation (FINA) Sports Medicine Committee, Lausanne, Switzerland
- Graham Jackson
- head of branch (retired)
- Catherine Olivier
- 6 Département de médecine sociale et préventive, École de santé publique, Université de Montréal, Montréal, Québec, Canada
- Amy Beth Coulson
- Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK
- Kara-Louise Royle
- Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK
- Charlotte Pawlyn
- Cancer Research UK London Research Institute, London, UK
- Anna Hockaday
- Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK
- Jennifer Bird
- Department of Haematology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
- Stella Bowcock
- Department of Haematology, Kings College Hospital NHS Foundation Trust, Princess Royal Hospital, Hull, UK
- Ruth de Tute
- Haematology Malignancy Diagnostic Service (HMDS), St James`s University Hospital, Leeds, West Yorkshire, UK
- Hayley Gardner
- Department of Haematology and Stem Cell Transplantation, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- Bryony Dawkins
- Academic Unit of Health Economics, University of Leeds, Leeds Institute of Health Sciences, Leeds, West Yorkshire, UK
- Rowena Henderson
- Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK
- Phillip Best
- Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK
- Bhuvan Kishore
- Department of Haematology and Stem Cell Transplantation, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- Mark Drayson
- Institute of Immunology and Immunotherapy, Department of Haematology, University of Birmingham, Birmingham, UK
- DOI
- https://doi.org/10.1136/bmjopen-2021-056147
- Journal volume & issue
-
Vol. 12,
no. 6
Abstract
No abstracts available.